Related news from
Fri, 04 Sep 2026 15:30:28 +0000	Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue? Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fri, 04 Sep 2026 13:37:00 +0000	Cencora Launches Cell and Gene Therapy Enablement for Health Systems COR launches CGT Enablement to help health systems build and scale cell and gene therapy programs with financial, operational and access support.
Fri, 04 Sep 2026 07:07:34 +0000	Is Cencora (COR) Still Undervalued On Higher 2026 Guidance And Strong Q3 Earnings? Cencora (COR) drew investor attention after third quarter results showed adjusted earnings per share of US$4.48, up 12% year over year, along with a higher fiscal 2026 adjusted earnings outlook. Cencora's latest earnings beat and higher 2026 guidance come after a strong run, with the share price up 22.6% over 90 days and a 1 year total shareholder return of 16.1%, building on a 5 year total shareholder return of 186.8%. Capitalize on Cencora's earnings momentum by scanning a hand picked group...
Thu, 03 Sep 2026 22:40:35 +0000	What Cencora (COR)'s Cell and Gene Push and Higher 2026 Outlook Means For Shareholders Cencora recently launched its Cell and Gene Therapy Enablement service through Accelerate Pharmacy Solutions to help health systems evaluate, build and scale advanced therapy programs, while also raising its fiscal 2026 adjusted earnings outlook following stronger-than-expected third-quarter results. The combination of expanded capabilities in cell and gene therapies and faster profit growth across its healthcare solutions segments highlights how Cencora is deepening its role in complex,...
Thu, 03 Sep 2026 19:22:00 +0000	Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.
Thu, 03 Sep 2026 13:11:39 +0000	Artisan Sold Cencora (COR) as Earnings Momentum Slowed Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equities rebounded sharply during the quarter, with the MSCI ACWI Index returning 15.3% as resilient economic growth, strong corporate earnings, and continued enthusiasm around artificial intelligence supported markets despite persistent inflation, […]
Wed, 02 Sep 2026 12:30:00 +0000	Cencora’s Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs CONSHOHOCKEN, Pa., September 02, 2026--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solutions, Cell and Gene Therapy Enablement is designed to help health systems strengthen operational readiness and program execution to reduce barriers to care and expand patient access to advanced therapies.
Fri, 04 Sep 2026 18:50:01 +0000	AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Fri, 14 Aug 2026 12:06:01 +0000	Cencora (COR): Leveraging Healthcare Growth and AI-Driven Productivity Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% […]
Fri, 04 Sep 2026 19:39:00 +0000	Here's Why You Should Retain Cencora Stock in Your Portfolio for Now Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.
Thu, 03 Sep 2026 21:52:55 +0000	Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore” On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his “absolute favorites” and mentioned its growing exposure to specialty pharmaceuticals and higher-margin healthcare services. Cardinal’s been running circles around McKesson and Cencora. They consistently put up the best numbers because this company has gradually become less of […]
Thu, 03 Sep 2026 12:22:00 +0000	Is Generics Still a Quiet Profit Engine for Cardinal Health? Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.
Mon, 31 Aug 2026 12:28:00 +0000	Beat the Market the Zacks Way: Accelerant, Insight, General Mills in Focus Accelerant, Shopify and Carpenter Technology delivered strong gains, while Zacks upgrades and model portfolios spotlight key performers.
Sat, 29 Aug 2026 16:05:01 +0000	Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
Wed, 26 Aug 2026 15:40:00 +0000	Camino Closes $5.8 Million Brokered Private Placement of Units and Concurrent $9.4 Million Non-Brokered Private Placement of Convertible Debentures "Not for distribution to United States news wire services or for dissemination in the United States."VANCOUVER, BC / ACCESS Newswire / August 26, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its previously announced private placements (together, the "Offering") for aggregate gross proceeds of C$15,223,109.
Mon, 24 Aug 2026 18:49:00 +0000	Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation? McKesson's double-digit earnings growth, specialty expansion and capital returns support the story, but a premium valuation leaves less room for error.
Mon, 24 Aug 2026 18:49:00 +0000	McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate McKesson raises fiscal 2027 EPS guidance as oncology, GLP-1 volumes and specialty distribution drive faster profit growth despite cash-flow pressure.
Fri, 14 Aug 2026 19:46:29 +0000	AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.
Sat, 29 Aug 2026 17:41:01 +0000	AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!